Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Cancer control domain
  • 6. Research
  • Prostate clinical trials participation

Prostate clinical trials participation

  • Charts and Tables

    Charts and Tables

    Figure 6.3

    Ratio of adult prostate cancer patients enrolled in clinical trials to number of incident cases, by disease site, four most common cancers and all cancers† — 2013 enrolment year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    †All cancers may include non-melanoma skin cancer patients.

    The overall clinical trial cases and incident cases included BC, AB, SK, MB, NB, NS, PE and NL.

    Incident cases are estimated for 2013 from the Canadian Cancer Society's Canadian Cancer Statistics.

    Data source: Provincial cancer agencies; Canadian Cancer Society, Canadian Cancer Statistics.

    Data Table

    CancerCases EnrolledCasesRatioLower bound of 95% confidence interval Upper bound of 95% confidence interval
    Breast4198,4400.0500.0450.054
    Prostate2919,1700.0320.0280.036
    Colorectal1348,6950.0150.0130.018
    Lung1058,9400.0120.010.014
    All Cancers†5,591138,5300.0400.0390.041

    + Expand Table

    †All cancers may include non-melanoma skin cancer patients.

    The overall clinical trial cases and incident cases included BC, AB, SK, MB, NB, NS, PE and NL.

    Incident cases are estimated for 2013 from the Canadian Cancer Society's Canadian Cancer Statistics.

    Data source: Provincial cancer agencies; Canadian Cancer Society, Canadian Cancer Statistics.

    Figure 6.4

    Ratio of adult prostate cancer patients enrolled in clinical trial to number of incident cases, by province — 2013 enrolment year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    * Suppressed due to small numbers.
    "-" Data not available.
    Incident cases are estimated for 2013 from the Canadian Cancer Society's Canadian Cancer Statistics.
    Data source: Provincial cancer agencies; Canadian Cancer Society, Canadian Cancer Statistics.

    Data Table

    ProvinceCases EnrolledCasesRatioLower bound of 95% confidence interval Upper bound of 95% confidence interval
    SK346500.0520.0360.072
    MB357200.0490.0340.067
    BC1333,5000.0380.0320.045
    NB237400.0310.020.046
    AB502,2000.0230.0170.03
    NS147200.0190.0110.032
    PE*****
    NL*****
    ON-----
    QC-----

    + Expand Table

    * Suppressed due to small numbers.
    "-" Data not available.
    Incident cases are estimated for 2013 from the Canadian Cancer Society's Canadian Cancer Statistics.
    Data source: Provincial cancer agencies; Canadian Cancer Society, Canadian Cancer Statistics.

  • Data specifications

    Data specifications

    Data and measurement considerations

    • The adult clinical trial indicator is a ratio not a rate. As such, the numerator is not a complete subset of the denominator. Cases included in the numerator could have been diagnosed in previous years and could be recurrent cases. The numerator is the total number of adult cancer patients (aged 19+) newly enrolled in all phases of therapeutic clinical trials or research studies (radiation, systemic and surgery trials only; curative, adjuvant/neoadjuvant or palliative) at provincial cancer centres in 2013. The denominator is the number of cancer incident cases in 2013. The projected cancer incident cases reported by the Canadian Cancer Society (CCS) were used for the purpose of this proxy indicator only; they should not be compared with the long-term outcomes incident cases.
    • The Alberta Clinical Trials (ACCT) database includes patients who were living outside Alberta, as long as they were enrolled in a clinical trial taking place in Alberta.

    Adult clinical trial participation by disease site

    • Definition: The ratio of the total number of adult patients (aged 19 and older) newly enrolled in cancer-related therapeutic trials or clinical research studies in 2013 to the projected number of new cancer cases (all ages) in 2013
    • Numerator: Number of cancer patients (aged ≥19) newly enrolled in cancer-related therapeutic clinical trials or clinical research at provincial cancer centres in 2013. For patients enrolled in multiple clinical trials, all occurrences are counted.
    • Denominator: Projected number of new invasive cancer cases (all ages) in 2013
    • Data source: Provincial cancer agencies or equivalent (numerator); Canadian Cancer Society, Canadian Cancer Statistics 2013 (denominator).
    • Measurement timeframe: 2013 enrolment year
    • Stratification variables: Disease site: Breast (female); 2. Prostate; 3. Colorectal; 4. Lung; 5. All invasive cancers (the numerator includes all invasive cancers; the denominator consists of all invasive cancers including in-situ bladder cancer cases).
    • Provinces submitting data: BC, AB, SK, MB, NB, NS, PE, NL
    • Province-specific notes: AB: For 2013, the total number of accruals for cancer patients (aged ≥19) included newly enrolled patients in cancer-related therapeutic trials or clinical research who were in the Alberta Cancer Clinical Trials (ACCT) database. If a patient had multiple clinical trial accruals in the given year, a patient would be counted for each accrual. The ACCT database also includes patients who were living outside of Alberta, as long as they were on a clinical trial in Alberta. The ACCT database includes both females and males in the Breast Tumour Group and may include clinical trials for non-melanoma skin patients.
    • General notes:
      1. “All cancers” may include non-melanoma skin patients.
      2. Incident cases are estimated for 2013, obtained from the Canadian Cancer Statistics.

    Adult clinical trial participation for prostate cancer

    • Definition: The ratio of the total number of prostate cancer patients (aged 19 and older) newly enrolled in cancer-related therapeutic trials or clinical research studies in 2013 to the projected number of new prostate cancer cases (all ages) in 2013
    • Numerator: Number of prostate cancer patients (aged ≥19) newly enrolled in prostate cancer-related therapeutic clinical trials or clinical research at provincial cancer centres in 2013. For patients enrolled in multiple clinical trials, all occurrences are counted.
    • Denominator: Projected number of new invasive prostate cancer cases (all ages) in 2013
    • Data source: Provincial cancer agencies or equivalent (numerator); Canadian Cancer Society, Canadian Cancer Statistics 2013 (denominator).
    • Measurement timeframe: 2013 enrolment year
    • Stratification variables: Province
    • Provinces submitting data: SK, MB, BC, NB, AB, NS, PE, NL
    • Province-specific notes: AB: For 2013, the total number of accruals for cancer patients (aged ≥19) included newly enrolled patients in cancer-related therapeutic trials or clinical research who were on the Alberta Cancer Clinical Trials (ACCT) database. If a patient went on multiple clinical trial accruals in the given year, a patient would be counted for each accrual. The ACCT database also includes patients who were living outside of Alberta, as long as they were on a clinical trial in Alberta.
    • General notes:
      1. Incident cases are estimated for 2013, obtained from the Canadian Cancer Statistics.
  • Related indicators

    Related Indicators

    Prostate cancer research investment

    Per capita investment (male population) in prostate cancer research, by province — 2005 and 2012
    View this indicator
    Adult clinical trial participation

    Ratio of adult patients (aged 19+) enrolled in clinical trials to the number of cancer incident cases of all cancers, by jurisdiction — 2012 to 2015 enrollment years
    View this indicator
    Cancer research investment

    Comparison of the relative burden of disease to the relative investment in research by disease site: Distribution of cancer research investment (2013), new cancer cases (2012) and cancer deaths (2011), by disease site, Canada
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation